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Evidence for angiotensin IV receptors in human collecting duct
cells
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Evidence for angiotensin IV receptors in human collecting duct cells.
Because angiotensin II (Ang II) has been found at high concentrations in
the proximal tubule fluid and because tubular brush border membranes
exhibit a marked capacity for degrading Ang II, we thought it of interest
to examine the binding sites for Ang 11(3-8) (referred to as Ang IV), a
metabolite of Ang 11, downstream in the nephron. We studied the binding
of ['25I]-Ang IV and also of I'251]-Sar', Ala8, Ang 11 to SV-40 transformed
human collecting duct cell (HCD) membranes. No specific binding site for
['251]-Sar', Ala8, Ang II and no Ang lI-dependent cytosolic calcium
response could be observed. Moreover, no signal for the human type I Ang
II receptor (hAT1) mRNA was present in HCD cells. In contrast,
['251]-Ang IV bound specifically to HCD cell membranes. Mean Kd and
Bmax values derived from saturation binding studies were 5.6 2.0 nM and
1007.6 140.2 fmol/mg protein, respectively. The rank order of affinity for
competitive Ang Il-related peptides was: Ang IV > Ang III > Ang II >
Ang 11(4-8) > Ang 11(1-7). ['25I]-Ang IV binding was not modified by
nonpeptide AT1 (losartan) or AT2 (PD123177) antagonists. GTPYS and
dithiotreitol did not affect [1251]-Ang IV binding. Ang IV stimulated
cAMP production by intact HCD cells in the presence of forskolin but did
not modify cGMP production or cytosolic calcium concentration. Taken
together, these results indicate that HCD cells represent a target site for
Ang IV but do not possess Ang II receptors.
Recent evidence indicates that the angiotensin II (Ang II) C
terminal hexapeptide, also designated as angiotensin IV (Ang
IV), is not an inactive metabolite but possesses the characteristics
of a real hormone with specific receptors and biological effects [1].
The kidney, which is one of the main target sites for Ang II, is also
rich in enzymes catabolizing this hormone including aminopepti-
dases, carboxypeptidases and neutral endopeptidase [2, 3]. Such
enzymes are present in high density at the luminal surface of the
proximal tubule cells. Moreover, it has been shown that the
concentration of Ang II in the proximal tubule fluid is high (10
nM) reaching 500 to 1000 times that simultaneously observed in
the plasma 1, 1 It is thus likely that high amounts of Ang IV are
formed in this part of the nephron. Collecting duct cells play a
major role in the final adjustment of the sodium balance. Their
principal cells possess aldosterone and argininc vasopressin re-
ceptors that control the activity of the amiloride-sensitive sodium
channel [6]. Early micropuncture studies suggested that Ang II
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might inhibit sodium reabsorption in the distal tubule [7]. Binding
studies on microdissected nephron segments demonstrated that
Ang II bound specifically to the rat cortical and inner medullary
collecting duct [8]. These studies could not distinguish the Ang II
receptor subtype. More recently, Zhuo et al, using high resolution
light and electronic autoradiography, did not detect any [125I]
Sar', Ala8, Ang II binding on the rat collecting duct after injection
of this tracer into the renal artery 191. In contrast, Terada et al,
using the reverse transcription-polymerase chain reaction tech-
nique in individual microdissected rat renal tubule segments,
found a marked signal for the type I Ang II (AT1) receptor in the
cortical collecting duct. Smaller but detectable bands were ob-
served in the outer and the inner medullary collecting ducts [10].
Our aim was to characterize the binding sites for Ang II and its
metabolite, Ang IV, in the principal cells of the human collecting
duct. Whereas no demonstration of the presence of specific Ang
II receptors could be made, we provided evidence for high-affinity
Ang IV binding sites with all the characteristics of the Ang IV
receptor previously described in other tissues [1, 11, 12].
Methods
Materials
Reagents for these studies were obtained as follows: [1251]-Sar1,
A1a8-Ang II and [1251]-Ang IV (74 TBq/mmol) from the "Centre
d'Etudes Nucléaires" (Gif-Sur-Yvette, France); [3H]-myoinositol
(2.7 TBq/mmol), [1251]-cyclic AMP, [1251]-cyclic GMP, anti-cyclic
AMP antibody and anti-cyclic GMP antibody from The Radio-
chemical Centre (Amersham, UK); culture media, antibiotics and
cell culture supplies from Gibco (Paisley, UK); newborn calf
serum (NCS) from Boehringer (Mannheim, Germany); ionomy-
cm and fura-2-acetoxymethyl ester from Calbiochem (San Diego,
CA, USA); Ang 11(3-8) (also referred to as Ang IV), Ang 11(4-8),
Ang 11(1-7) and human atrial natriuretic factor (ANF) from
Peninsula (London, UK). Ang 11 was a gift from Ciba-Geigy
(Basel, Switzerland). Losartan and its metabolite, EXP 3174, two
nonpeptide AT1 antagonists, were donated by Merck, Sharp and
Dohme Research Laboratories (West Point, PA, USA); CV
11974, another AT1 antagonist, and PD 123177, an AT2 antago-
nist, were donated by Takeda (Tokyo, Japan) and Parke-Davies
(Ann Arbor, MI, USA), respectively. All other reagents were
from Sigma (St. Louis, MO, USA).
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Cell culture
The human collecting duct cell line (HCD) was established
previously by transfection of a human tubular cell suspension with
a replication-defective strain of SV4O virus. This cell line has been
previously identified and expresses the essential characteristics of
the principal cells [131. Cells were regularly cultured at 37°C in an
atmosphere of 5% C02-95% air in a hormonally-defined medium
(DMEM-HAM's F12, 1:1 (vol/vol); transferrin, 5 jig/ml; sodium
selenate, 50 nM; glutamine, 2 mM; dexamethasone, 50 nM; insulin,
5 g/ml; HEPES, 20 mii, pH 7.4) containing 2% NCS. They were
seeded at a density of 10,000 cells/cm2 in 12-well plates or 100 mm
Petri dishes. Cultures were re-fed with fresh medium every two to
three days. All the experiments presented in this study were
performed on confluent cells from passages 20 to 47 that had been
cultured for five days.
Cell membrane preparation
Membranes of HCD cells were prepared according to the
technique utilized by Hall et al for cultured vascular smooth
muscle cells with minor modifications [11]. HCD cells grown at
confluence were washed once at 37°C in phosphate-buffered
saline (in mM: NaCI, 150; Na2 HPO4, 9.2; NaH2PO4, 2.3; pH 7.4).
This was followed by the addition to the culture dish of 2 ml of
cold (4°C) isotonic buffer (in mM: NaCI, 150; Tris, 50; EDTA, 1;
phenylmethylsulfonyl fluoride, 1; bestatin, 0.01; pH 7.4). Cells
were then removed from the plates with a rubber policeman and
homogenized in 5 ml of assay buffer for approximately 10 seconds
(Polytron, Brinkman Instruments). The homogenate was centri-
fuged at 40,000 g for 20 minutes at 4°C, the supernatant was
discarded, the pellet was rehomogeneized in the buffer and the
centrifugation was repeated. The final pellet was resuspended in
the assay buffer to a working concentration of approximately 1 mg
protein/mi as determined by the method of Lowry et al [141. The
membrane suspension was utilized immediately following prepa-
ration.
Binding studies
Membrane receptor binding assays were performed using [125l]
Sar1, Ala8, Ang II or ['251]-Ang IV according to Hall et al with
minor modifications [11]. Duplicate samples were incubated at
37°C under continuous shaking for 120 minutes with 0.4 flM of
[1251-Ang IV or 0.9 nM of ['251j-Sar1, Ala8, Ang II in a total
volume of 250 il of assay buffer (NaCI, 150 mM; Tris, 50 mM;
EDTA, 1 mM; PMSF, 1 mtvi; bestatin, 20 jiM; BSA, 0.1%; pH 7.4)
containing 100 jig of membrane protein. Bound and free ligands
were separated at the end of each experiment by addition of 4 ml
of ice-cold phosphate-buffered saline and vacuum filtration
through a Whatman GF/B filter followed by three additional
washes (4 ml) with phosphate-buffered saline. The [1251] radioac-
tivity retained by the filters was counted in a LKB (Malmoe,
Sweden) gamma counter with 60% counting efficiency. Kinetic
studies, competitive binding experiments and saturation binding
experiments were performed. The binding parameters, Kd and
were derived from the Scatchard's transformation of the
data obtained in the latter two study types. Nonspecific binding
was measured in the presence of 1 jiM unlabeled ligand and
specific binding was calculated as the difference between total and
nonspecific binding. It was expressed as femtomoles of [128I-Ang
IV or ['251]-Sar', Ala8, Ang 11 bound per mg of protein.
For G-protein linkage experiments, the membrane prepara-
tions were first preincubated at 22°C for 60 minutes in the assay
buffer supplemented with 5 mM MgC12 and containing increasing
concentrations of GTP-yS (0.1 to 100 jiM). Pretreated membranes
were then studied in equilibrium binding experiments.
Binding studies were also performed using intact cells in
monolayers. Confluent cells in 12-well plates were rinsed three
times with 0.15 NI NaCl. Then they were incubated at 22°C for 30
minutes with f'251-Ang IV (0.15 nM) in 500 jil of buffer (NaCI,
135 mM; Tris, 20 mM; glucose, 5 mM; KCI, 10 mM; NaCH3COO, 10
mM; CaCl2, 2 mM; BSA, 0.2%; pH 7.4) in the presence of
increasing concentrations of unlabeled Ang IV (1 n to 10 j.LM) or
of various aminopeptidase N (APN) inhibitors. At the end of the
incubation period, the medium was removed and the cells were
rinsed three times with 2 ml of ice-cold 0.15 M NaCI. The cells
were then dissolved in I M NaOH and [125J] radioactivity was
counted.
Enzyme assays
APN activity was measured on cell membranes as previously
described [151. Membranes (100 jig) were suspended in 0.5 ml of
Ca2-free phosphate-buffered saline additioned with 1 N1
MgCl2. The enzymatic reaction was started by addition of I mri
alanine-p-nitroanilide as substrate. Incubation was carried out
with gentle agitation for 5 to 20 minutes under zero-order kinetic
conditions. The amount of p-nitroanilide formed was measured in
the supernatant at an O.D. of 405 nm. Cell-free and substrate-free
blanks were run in parallel. Enzyme activity was expressed as
nmol p-nitroanilide formed per mm per mg of protein.
Cyclic AMP and cyclic GMP assays
HCD cells grown at confluence in 12-well trays were incubated
for 15 minutes at 37°C in their culture medium in the presence of
0.1 mM 3-isohutyl-1-methyl xanthine (IBMX), a phosphodiester-
ase inhibitor. The medium was then discarded and replaced by the
same medium with or without the agents to be tested: Ang IV (0.1
/.LM) and forskolin (100 jiM), alone or in combination for cyclic
AMP, Ang IV (0.1 jiM) and ANF (0.1 jiM), alone or in combina-
tion for cyclic GMP. After a five minute incubation at 37°C, the
medium was quickly recovered and the reaction was stopped by
adding 0.5 ml of ice-cold 0.1 M HCI. After 10 minutes at 4°C, the
supernatant was collected and added to the medium. Only the
resulting specimens for cyclic GMP determination were acety-
lated. Then all specimens were diluted in 50 mM sodium acetate
buffer, pH 6.2. Cyclic nucleotides were measured by radioimmu-
noassays using specific anti-cyclic AMP and anticyclic GMP
antibodies. Results were expressed as pmol/mg/5 mm.
Inositol phosphate analysis
Inositol phosphates (IPs) were measured as described [16].
After the cells had reached subconfluency, culture medium was
removed and cells were placed in inositol-deficient Waymouth
medium containing 1.1 MBq/ml of [3H1-myoinositol (2 ml per
well) for 48 hours at 37°C. After 15 minutes preincuhation with 10
m of lithium chloride, 0.1 jiM of Ang IV was added. A positive
control was performed with bradykinin at the same concentration.
The incubation was terminated by quickly aspirating the medium
and adding 2 ml of ice-cold 5% trichloroacetic acid. Cells were
scraped away from the wells, washed once more with 5% trichlo-
roacetic acid and the aqueous phase was extracted in diethylether.
hAT1-R
f3-Actin
HMC HCD
Samples were adjusted to pH 7.0 with 50 m of sodium tetrabo-
rate and then loaded into 2 ml Dowex AG1-X8 anion exchange
resin columns (Biorad). The columns were washed with 10 ml of
water and 10 ml of 5 mmol/liter sodium tetraborate. IPs were then
eluted with 10 ml of increasing concentrations of ammonium
formate in 0.1 ifiM formic acid. Five milliliters of each collected
fraction were mixed with scintillation fluid and counted in a beta
counter (LKB).
Cytosolic free calcium determination
Cells were cultured on thin glass microscope coverslips pre-
coated with 0.2% gelatin and were studied at subconfluence. Cells
were loaded with 1.5 I.LM Fura 2/AM at 37°C for 90 minutes. For
measurements of fluorescence, each coverslip was placed on the
stage of the inverted microscope and one cell was selected. The
sample was then superfused at a rate of 0.6 mI/mm at 37°C with
basal medium or with the solution to be tested. Fura 2 was
alternatively excited at wavelengths of 340 and 380 nm using a
75-W xenon light source, filters, and a chopper (PTI Photoscan II
System; Kontron). The fluorescence intensities (S at 340 nm and
L at 380 nm) issued from the selected cell and delimited by means
of an adjustable window were measured. [Ca21 was calculated
from the following equation: [Ca2] = K1[(R — R,,j)/(R,nax
R)1(L,,=x/Lmin) where K = 224 nM, R S/L, and Lmn, Lmux,
and arc L and R values at 0 and saturating concentra-
tions of calcium, respectively. L,, Lr.,in, Rmin and Ra were
determined by external calibration as previously described [17].
Preparation of RNA and Northern analysis of hAT1 receptor
Total RNA from human collecting duct cells was extracted by
the phenol-chloroform method and precipitated with 3 M LiCI
[18]. RNA concentration and purity were determined from the
absorhance readings at 260 and 280 nm. Total RNA was then
fractionated by electrophoresis in agarose gel and transferred to a
Nylon Genescreen Plus membrane (New England Nuclear, Bos-
ton, MA, USA). After prehybridization, the blot was hybridized
for 16 hours at 42°C with an [a32P1-lahclcd eDNA probe specific
for the human AT1 receptor [19]. Total RNA from human
mesangial cells was used as a positive control [201.
After hybridization, the filters were washed three times at 42°C
for 20 minutes in 2 x SSC (1 X SSC is 0.15 M NaCI and 0.015 M
sodium citrate, pH 7.0) containing 0.1% sodium dodecylsulfate
(SDS) and exposed to a Fuji X-ray film at —80°C in the presence
of intensiiing screens. The same filter was dehybridized by
boiling for 15 minutes in 0.1 X SSC containing 1% SDS and
rehybridized with a [32P]-laheled -actin eDNA probe.
Results
Binding studies of /'251J-Sar', Ala8, Ang II on HCD cell
membranes and absence of hA T, mRNA expression in HCD cells
Our initial aim was to examine whether or not there were
specific binding sites for Ang II at the surface of HCD cells.
Therefore, we studied ['251]-Sar1, Ala5, Ang 11 binding to HCD
cell membranes. Only nonspecific binding sites could be detected
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Fig. 1. ['251J-Sar', Ala8, Ang II binding to HCD cell membranes in the
presence of increasing concentrations of Ang II. Data arc means s of 3
individual experiments (each with duplicate samples) are shown.
Fig. 2. Northern blot analysis showing that hAT, mRNA is expressed in
human mesangial cells (HMC) but absent in HCD cells. -actin mRNA was
used as a control.
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Fig. 3. Time-course study of f'251J-Ang IV binding to HCD cell membranes.
A representative experiment is shown. Each point is the mean of
duplicates. Specific binding was calculated as the difference between total
and nonspecific binding.
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as shown by the absence of displacement of the bound tracer evenS
at high concentrations of Ang 11 (Fig. 1). We also examined
whether or not hAT, mRNA was expressed in HCD cells. The
Northern blot technique using a human AT1 cDNA specific probe
did not reveal any signal. Positive controls were obtained in the
same experiment with human mesangial cells (Fig. 2). These
initial results led us to study the binding of Ang IV which could
have been formed locally after cleavage of the two N-terminal
amino acids of the tracer.
Binding studies of ['251]-Ang Il/on HCD cell membranes
The results observed differed substantially from those obtained
with ['251]-Sar', Ala8, Ang II. Kinetic studies showed that [125I]
Ang IV binding to cell membranes reached a plateau after 90
minutes incubation that persisted up to 180 minutes. At equilib-
rium, nonspecific binding represented 15% of total binding (Fig.
3). Saturation binding experiments were performed at equilibrium
after 120 minutes incubation. The amount of [12511-Ang IV
specifically bound increased curvilinearly as a function of [125J]
Ang IV concentration in the medium. Scatchard's transformation
of the data revealed that there was a single group of receptor sites
(Fig. 4). The mean Kd and Bnax values obtained from three
experiments were 5.6 2.0 n and 1007.6 140.2 fmol/mg
membrane protein. Competitive inhibition of binding of [125I]
Ang IV to HCD cell membranes at equilibrium in the presence of
increasing concentrations of Ang IT-related peptides indicated a
high specificity for Ang IV (Fig. 5). Scatchard's transformation of
these data that had been obtained over a large range of concen-
trations provided results in the same range as those found in
saturation binding experiments. There was a single group of
receptors, and mean K,, and Bmax values derived from three
experiments were 9.0 0.78 n and 1368 350 fmol/mg. The
rank order affinity of competitive Ang 11-related peptide was as
follows: Ang IV > Ang III > Ang II > Ang 11(4-8) > Ang II
(1-7). ['251j-Ang IV binding to HCD cell membranes was not
affected by nonpeptide AT1 (losartan) or AT2 (PD123 177) antag-
onists (Fig. 6). Other AT1 antagonists (EXP 3174 and CV 11974)
were tested with the same negative results (results not shown).
These data indicated that the Ang IV binding sites present on the
cell membranes did not correspond to classical AT1 or AT2
receptors. They also were distinct from APN, one of the main
enzymes hydrolyzing Ang III and Ang IV [21, 22], since binding
studies were performed in the presence of an excess of bestatin,
an APN inhibitor. A non-hydrolysable GTP analogue, GTP-yS,
did not affect the {'25I-Ang IV binding to HCD cell membranes
over a large range of concentrations (0.1 to 100 ,tLM). Negative
results were also obtained in the presence of increasing concen-
trations of dithiotreitol (0.01 to 10 mM). The latter results
confirmed that the binding sites studied were distinct from the
AT, receptors.
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Fig. 4. Saturation binding study of /'251]-Ang IV to
HCD cell membranes. One representative
experiment is shown. Each point is the mean of
duplicates. The Scatchard's transformation of the
data are shown in the inset (K,, = 2.3 nM; Bmax =
894.4 fmol/mg). Two additional studies were
performed.
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Fig. 5. Competitive inhibition of binding of /'251j-Ang IV to HCD cell
membranes in the presence of increasing concentrations of Ang IV (S), Ang
III (0), Ang II (LI), Ang II (4-8) () and Ang II (1-7) (A). Data are the
means of 2 to 4 individual experiments (each with duplicate samples).
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Binding studies of /'251J-Ang IV on intact HCD cells
[1251J-Ang IV specifically bound to HCD cells as shown by the
marked displacement of the tracer (85%) obtained in the pres-
ence of an excess of unlabeled Ang TV (Fig. 7). Unexpectedly,
bestatin and amastatin, two competitive inhibitors of aminopep-
tidase N activity, were as potent competitors as unlabeled Ang IV
with a 50% inhibitory concentration (IC.1) of approximately 0.1
1kM for the three agents. A noncompetitive inhibitor of aminopep-
tidase N, 1,10 phenanthrolin, also exhibited an inhibitory potency
but at a much lesser degree (IC50 = 56.4 jIM).
Biological effects of Ang IV on intact HCD cells in monolayer
Ang IV (100 nM) did not modify intracellular calcium concen-
tration [Ca2]1 or inositol phosphate formation, thus indicating
that Ang IV did not stimulate the phospholipase C pathway.
Positive controls were obtained in both cases with bradykinin (100
nM). We also verified that Ang II was inactive, which confirmed
the absence of AT1 receptors in HCD cells. The results of [Ca2
determinations are shown in Figure 8. The only biological effect
observed was the Ang TV-stimulated cyclic AMP production in
the presence of 100 jIM forskolin (261 33 and 178 19
pmol/mgIS mm with and without 0.1 jIM Ang IV, respectively; N =
6, P < 0.05). In contrast, Ang IV did not enhance basal cyclic
AMP formation (22 4 and 23 5 pmol/mg!5 mm with and
without Ang TV, respectively). Ang IV also did not affect cyclic
GMP production in HDC cells (0.35 0.05 and 0.40 0.06
pniol/mgIS mm with and without 0.1 jIM Ang IV, respectively). A
positive control was obtained with 0.1 jIM ANF (112.0 20.1
pmol/mgIS mm). Ang IV also did not modify the ANF-dependent
cyclic GMP concentration (104.1 21.2 pmol/mg/5 mm).
Enzyme studies in HCD cell membranes
APN activity was detected in HCD cell membranes at a level of
17.9 4.0 nmol/min/mg (N = 4). Bestatin inhibited APN activity
at the concentrations present in the medium for membrane
preparation and in the incubation medium (10 and 20 jIM,
respectively).
Discussion
We report in the present study that a human renal cell line
deriving from the cortical collecting duct and expressing principal
cell characteristics [13] possesses specific receptors for Ang IV. In
contrast, no Ang II receptor could be demonstrated.
Evidence for Ang IV specific receptors on HCD cell mem-
branes is supported by the following findings: (1) ['25T-Ang IV
bound to cell membranes in a specific saturable manner. Equilib-
rium of binding occurred after 90 minutes of incubation and
nonspecific binding represented only 15% of total binding when
the plateau had been reached. There was a single group of
receptor sites with a Kd of approximately 5 n. This value is in
accordance with those reported by others [11, 23]. Competitive
inhibition experiments confirmed the high affinity of the receptor
for Ang IV with a lesser inhibitory potency for the other Ang
Il-related peptides. The rank order of potency was identical to
that previously reported for Ang IV receptors in other tissues
including bovine adrenal cortical membranes [1], bovine vascular
smooth muscle cells [11] and cultured rabbit cardiac fibroblasts
[23]. In particular, Ang II was 1,000 times less potent than Ang IV
in the displacement of ['251]-Ang IV from its receptor. (2) Ang IV
binding sites did not recognize AT1 (losartan, EXP 3174, CV
11974) and AT7 (PD 123177) antagonists. (3) ['251I-Ang IV
binding was neither affected by GTP-yS nor by dithiotreitol,
confirming that the binding sites studied were different from the
two classical Ang TI receptor subtypes. The lack of effect of
GTPyS suggesting non-G-protein linkage is in agreement with
other reports [12, 23]. In contrast, a stimulatoty effect of dithio-
treitol on Ang IV binding to bovine adrenal cortex membranes
has been reported by Jarvis and Gessner [24]. (4) Ang IV
stimulated cyclic AMP production by HCD. However, the degree
of stimulation was low and activation of the catalytic site by
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Fig. 6. Lack of competitive effect of losartan (U), an AT1 antagonist, and of
PD123177 (A), an AT2 antagonist, on ['251J-Ang IV binding to HCD cell
membranes. The competitive inhibition curve in the presence of unlabeled
Ang IV (A) is also shown. Data are the means of 2 to 3 individual
experiments (each with duplicate samples).
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Fig. 7. Competitive inhibition of binding of f'251J-Ang IV to HCD cells in
the presence of increasing concentrations of unlabeled Ang IV (•), bestatin
(0), amastatin (LII), and 1,10 phenantroline (A). Intact cells in monolayers
exposing their apical poles to the medium were studied. Data are the
means of 3 individual experiments (each with duplicate samples).I I I -
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forskolin was necessary to obtain a response. Such a combination
of forskolin and hormones has been previously used to reveal
cyclic AMP responses to hormones that are low or not observed in
the absence of forskolin. It is generally admitted that forskolin
through its synergistic interaction with hormones acts to increase
a small hormone-dependent response that is already present in
the unresponsive cells [251. (5) Ang IV binding sites are not
hydrolyzing enzymes, in particular not APN, since bound [12511
Ang IV was not displaced by an excess of bestatin, an APN
inhibitor, which was regularly present in the incubation medium.
To determine the cellular localization of Ang IV receptors, we
studied the binding of ['251]-Ang IV to intact HCD cells in
monolayers that exposed their apical membranes to the incuba-
tion medium. [125I-Ang IV binding to intact cells was completely
displaced by APN inhibitors, whereas opposing results were
obtained using cell membranes, strongly suggesting that the
receptors for Ang IV are located mainly at the basolateral pole of
the HCD cells. The binding sites present on the apical membrane
are likely to be enzyme proteins, in particular APN, since their
affinity for Ang IV was the same as that of two APN competitive
inhibitors, bestatin and amastatin. However, this affinity was lower
than that of Ang IV for the specific receptor identified on the
membrane preparation, since 50% of maximum binding of [125J]
Ang IV was displaced by 1 n of Ang IV on the membranes and
100 nM of Ang IV on the cells. This finding is in agreement with
the generally accepted view that hormones have a greater affinity
for their receptors than for their hydrolyzing enzymes. The
exclusive location of APN at the apical side has already been
reported in cultured tubular cells [26]. However, even in small
numbers, Ang IV specific receptors should be present in intact
cells on their luminal membranes, since by using this preparation
an increase in cyclic AMP in the presence of Ang IV and forskolin
was observed. Such a hypothesis would be in agreement with the
intraluminal formation of Ang IV from Ang II via the successive
actions of APA and APN that are present all along the ncphron
[27, 28], and also with the previously published report of Dulin et
al [29] showing Ang IV receptors both on the basolateral mem-
branes and the brush border membranes purified from the rabbit
renal cortex. Alternatively, as recently observed in cultured bovine
adrenal medullary cells [30], Ang II could be converted into Ang
IV by an endosomal pathway. However, this would require an
internalization of Ang II, which is unlikely due to the absence of
Ang II receptors on HCD cells.
Ang IV specific binding sites in the kidney have been previously
localized to the outer stripe of the medulla in the rat using
autoradiographic analysis [30]. They are also present in the guinea
pig and the monkey kidney [1, 31]. More precisely, Dulin et al
demonstrated specific binding of Ang IV to rabbit basolateral
membranes and brush border membranes of the renal cortex [29].
Ang IV in contrast with Ang II increases cortical blood flow [1]. It
also stimulates DNA and RNA synthesis in cultured rabbit cardiac
fibroblasts [23]. The role of Ang IV specific receptors in the
human collecting duct remains unknown. Stimulation of cyclic
AMP in HCD cells by Ang IV could influence water and ionic
transports that are sensitive to cyclic AMP concentration through
protein kinase A activation and channel protein phosphorylation.
Indeed, cyclic AMP activates apical Na entry in the collecting
duct which results, via an increase in intracellular sodium concen-
tration, in the stimulation of the basolateral Na/Ca2 exchanger
[32].
Finally, we could not find any evidence for the presence of Ang
II receptors on HCD cells. There was no specific binding of Sar',
Ala8, Ang II to cell membranes and no cytosolic calcium response
after exposure of the cells to 0.1 LM of Ang II. Furthermore, no
hAT mRNA signal was found using the Northern blot technique.
It is possible that the transfected cell line studied exhibits modi-
fied phenotypic characteristics resulting in the lack of expression
of Ang II receptors. However, this seems unlikely since the human
renal cell line utilized has been shown to possess most of the
receptors of the parental cells [13, 33].
In conclusion, this study demonstrates that the human collect-
ing duct is not a target site for Ang II hut for its metabolite, Ang
IV. Further studies are needed to examine the physiological
consequences of this finding.
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